Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

Metabolic syndromes and malignant transformation: where the twain shall meet.

Bhagwat N, Levine RL.

Sci Transl Med. 2010 Oct 20;2(54):54ps50. doi: 10.1126/scitranslmed.3001669.

PMID:
20962328
2.

IDH mutations in glioma and acute myeloid leukemia.

Dang L, Jin S, Su SM.

Trends Mol Med. 2010 Sep;16(9):387-97. doi: 10.1016/j.molmed.2010.07.002. Epub 2010 Aug 5. Review.

PMID:
20692206
3.

IDH mutations in cancer and progress toward development of targeted therapeutics.

Dang L, Yen K, Attar EC.

Ann Oncol. 2016 Apr;27(4):599-608. doi: 10.1093/annonc/mdw013. Review.

PMID:
27005468
4.

2-hydroxyglutarate accumulation caused by IDH mutation is involved in the formation of malignant gliomas.

Sonoda Y, Tominaga T.

Expert Rev Neurother. 2010 Apr;10(4):487-9. doi: 10.1586/ern.10.19. Review. No abstract available.

PMID:
20367200
5.

Isocitrate dehydrogenase mutations: a challenge to traditional views on the genesis and malignant progression of gliomas.

Weller M, Wick W, von Deimling A.

Glia. 2011 Aug;59(8):1200-4. doi: 10.1002/glia.21130. Epub 2011 Feb 3. Review.

PMID:
21294161
6.

Metabolism of glioma and IDH1/IDH2 mutations.

Rossetto M, Ciccarino P, Boisselier B, Labussiere M, Sanson M.

Rev Neurol (Paris). 2011 Oct;167(10):699-703. doi: 10.1016/j.neurol.2011.08.002. Epub 2011 Aug 31. Review.

PMID:
21885076
7.

Isocitrate dehydrogenase mutations in gliomas.

Waitkus MS, Diplas BH, Yan H.

Neuro Oncol. 2016 Jan;18(1):16-26. doi: 10.1093/neuonc/nov136. Epub 2015 Jul 16. Review.

8.

Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities.

Cairns RA, Mak TW.

Cancer Discov. 2013 Jul;3(7):730-41. doi: 10.1158/2159-8290.CD-13-0083. Epub 2013 Jun 24. Review.

9.

Mutations in the isocitrate dehydrogenase genes IDH1 and IDH2 in tumors.

Schaap FG, French PJ, Bovée JV.

Adv Anat Pathol. 2013 Jan;20(1):32-8. doi: 10.1097/PAP.0b013e31827b654d. Review.

PMID:
23232569
10.

What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer.

Losman JA, Kaelin WG Jr.

Genes Dev. 2013 Apr 15;27(8):836-52. doi: 10.1101/gad.217406.113. Review.

11.

Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development.

Dang L, Su SM.

Annu Rev Biochem. 2017 Jun 20;86:305-331. doi: 10.1146/annurev-biochem-061516-044732. Epub 2017 Apr 3. Review.

PMID:
28375741
12.

Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate.

Andronesi OC, Rapalino O, Gerstner E, Chi A, Batchelor TT, Cahill DP, Sorensen AG, Rosen BR.

J Clin Invest. 2013 Sep;123(9):3659-63. doi: 10.1172/JCI67229. Epub 2013 Sep 3. Review.

13.

Glioma-derived mutations in IDH: from mechanism to potential therapy.

Fu Y, Huang R, Du J, Yang R, An N, Liang A.

Biochem Biophys Res Commun. 2010 Jun 25;397(2):127-30. doi: 10.1016/j.bbrc.2010.05.115. Epub 2010 May 27. Review.

PMID:
20510884
14.

IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives.

Yang H, Ye D, Guan KL, Xiong Y.

Clin Cancer Res. 2012 Oct 15;18(20):5562-71. doi: 10.1158/1078-0432.CCR-12-1773. Review.

15.

2-Hydoxyglutarate: D/Riving Pathology in gLiomaS.

Wahl DR, Venneti S.

Brain Pathol. 2015 Nov;25(6):760-8. doi: 10.1111/bpa.12309. Review.

16.

Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism.

Reitman ZJ, Yan H.

J Natl Cancer Inst. 2010 Jul 7;102(13):932-41. doi: 10.1093/jnci/djq187. Epub 2010 May 31. Review.

17.

Molecular Pathways: IDH2 Mutations-Co-opting Cellular Metabolism for Malignant Transformation.

Stein EM.

Clin Cancer Res. 2016 Jan 1;22(1):16-9. doi: 10.1158/1078-0432.CCR-15-0362. Epub 2015 Nov 9. Review.

18.

Cancer-associated IDH mutations: biomarker and therapeutic opportunities.

Yen KE, Bittinger MA, Su SM, Fantin VR.

Oncogene. 2010 Dec 9;29(49):6409-17. doi: 10.1038/onc.2010.444. Epub 2010 Oct 25. Review.

PMID:
20972461
19.

The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation.

Molenaar RJ, Radivoyevitch T, Maciejewski JP, van Noorden CJ, Bleeker FE.

Biochim Biophys Acta. 2014 Dec;1846(2):326-41. doi: 10.1016/j.bbcan.2014.05.004. Epub 2014 May 28. Review.

PMID:
24880135
20.

Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer.

Clark O, Yen K, Mellinghoff IK.

Clin Cancer Res. 2016 Apr 15;22(8):1837-42. doi: 10.1158/1078-0432.CCR-13-1333. Epub 2016 Jan 27. Review.

Supplemental Content

Support Center